NASDAQ:BGNEBeigene Stock Price, Forecast & News

Beigene's stock was trading at $145.69 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BGNE stock has increased by 29.9% and is now trading at $189.18. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Beigene.

Beigene is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Beigene.

Beigene Ltd (NASDAQ:BGNE) issued its earnings results on Monday, May, 11th. The company reported ($4.70) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($4.85) by $0.15. The business earned $52.06 million during the quarter, compared to analysts' expectations of $27 million. Beigene had a negative return on equity of 68.64% and a negative net margin of 284.45%. View Beigene's earnings history.

11 analysts have issued twelve-month price targets for Beigene's stock. Their forecasts range from $165.00 to $230.00. On average, they expect Beigene's stock price to reach $202.81 in the next year. This suggests a possible upside of 7.2% from the stock's current price. View analysts' price targets for Beigene.

Media coverage about BGNE stock has trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Beigene earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Beigene.

Some companies that are related to Beigene include Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Genmab A/S (GMAB), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT) and Teva Pharmaceutical Industries (TEVA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Beigene investors own include NVIDIA (NVDA), Alibaba Group (BABA), Crispr Therapeutics (CRSP), Square (SQ), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Intuitive Surgical (ISRG), InVitae (NVTA), AbbVie (ABBV) and JD.Com (JD).

(BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BGNE stock can currently be purchased for approximately $189.18.

Beigene has a market capitalization of $14.63 billion and generates $428.21 million in revenue each year. The company earns $-948,630,000.00 in net income (profit) each year or ($15.80) on an earnings per share basis. Beigene employs 3,500 workers across the globe.

The official website for Beigene is www.beigene.com.

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]